This medicinal product is for diagnostic use only
PYLCLARITM is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:
This medicinal product is for diagnostic use only
PYLCLARI® is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:
Detailed recommendations for the use of this product can be found in the Summary of Product Characteristics (SmPC)
Looking for training on how to interpret piflufolastat (18F) images?
Refresh your knowledge on guidelines and test yourself with some clinical cases interpretations
Error: Formulario de contacto no encontrado.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See SmPC, section 4.8 for how to report adverse reactions.
Copyright © 2017-2023. Website content is subject to copyright protection.
Please refer to Terms of Use for more information.
The information on this page is intended for use by healthcare providers only. By continuing, you automatically confirm that you are a professional healthcare provider in a European country
You are now pre-registered for PYLCLARI™ training. We have received your details and are currently processing your request. Once this is completed, Curium will contact you with instructions on how to access the content.
